JP2023548590A - 小細胞肺がんの分類と治療のための方法およびシステム - Google Patents

小細胞肺がんの分類と治療のための方法およびシステム Download PDF

Info

Publication number
JP2023548590A
JP2023548590A JP2023527276A JP2023527276A JP2023548590A JP 2023548590 A JP2023548590 A JP 2023548590A JP 2023527276 A JP2023527276 A JP 2023527276A JP 2023527276 A JP2023527276 A JP 2023527276A JP 2023548590 A JP2023548590 A JP 2023548590A
Authority
JP
Japan
Prior art keywords
sclc
subject
targeting agent
proteins
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023527276A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023548590A5 (https=
Inventor
エリザベス エム． パーク
ローレン エイ． バイヤーズ
カール エム． ガイ
ジョン ブイ． ヘイマッチ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of JP2023548590A publication Critical patent/JP2023548590A/ja
Publication of JP2023548590A5 publication Critical patent/JP2023548590A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4264—Cancer antigens from embryonic or fetal origin
    • A61K40/4266—Carcinoembryonic antigen [CEA]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/55—Lung

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2023527276A 2020-11-06 2021-11-05 小細胞肺がんの分類と治療のための方法およびシステム Pending JP2023548590A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063110664P 2020-11-06 2020-11-06
US63/110,664 2020-11-06
PCT/US2021/058218 WO2022098979A1 (en) 2020-11-06 2021-11-05 Methods and systems for classification and treatment of small cell lung cancer

Publications (2)

Publication Number Publication Date
JP2023548590A true JP2023548590A (ja) 2023-11-17
JP2023548590A5 JP2023548590A5 (https=) 2024-11-12

Family

ID=81457377

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023527276A Pending JP2023548590A (ja) 2020-11-06 2021-11-05 小細胞肺がんの分類と治療のための方法およびシステム

Country Status (8)

Country Link
US (1) US20230405117A1 (https=)
EP (1) EP4240755A4 (https=)
JP (1) JP2023548590A (https=)
KR (1) KR20230104233A (https=)
CN (1) CN116997572A (https=)
AU (1) AU2021372988A1 (https=)
CA (1) CA3200665A1 (https=)
WO (1) WO2022098979A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4577578A1 (en) 2022-08-22 2025-07-02 Abdera Therapeutics Inc. Dll3 binding molecules and uses thereof
CN116466089B (zh) * 2023-04-27 2025-10-31 杭州华得森生物技术有限公司 采用微流控芯片与多重免疫荧光探针技术的基于sclc分子分型的ctc的检测试剂盒及其鉴定方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011093097A1 (ja) * 2010-01-29 2011-08-04 株式会社未来創薬研究所 抗dll3抗体
JP2015509947A (ja) * 2012-02-24 2015-04-02 ステム セントリックス， インコーポレイテッド Ｄｌｌ３モジュレーター及び使用方法
JP2018506981A (ja) * 2015-02-23 2018-03-15 アッヴィ・ステムセントルクス・エル・エル・シー 抗ｄｌｌ３キメラ抗原受容体および使用方法
WO2019234220A1 (en) * 2018-06-09 2019-12-12 Boehringer Ingelheim International Gmbh Dll3-cd3 bispecific antibodies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5117765B2 (ja) * 2007-05-28 2013-01-16 国立大学法人 東京大学 抗ｒｏｂｏ１抗体を含むｐｅｔ用腫瘍診断剤

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011093097A1 (ja) * 2010-01-29 2011-08-04 株式会社未来創薬研究所 抗dll3抗体
JP2015509947A (ja) * 2012-02-24 2015-04-02 ステム セントリックス， インコーポレイテッド Ｄｌｌ３モジュレーター及び使用方法
JP2018506981A (ja) * 2015-02-23 2018-03-15 アッヴィ・ステムセントルクス・エル・エル・シー 抗ｄｌｌ３キメラ抗原受容体および使用方法
WO2019234220A1 (en) * 2018-06-09 2019-12-12 Boehringer Ingelheim International Gmbh Dll3-cd3 bispecific antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RUDIN, CHARLES M. ET AL.: "Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data", PMC [ONLINE], JPN6025052235, 1 May 2020 (2020-05-01), ISSN: 0005758787 *

Also Published As

Publication number Publication date
EP4240755A4 (en) 2024-12-18
CN116997572A (zh) 2023-11-03
AU2021372988A1 (en) 2023-06-22
US20230405117A1 (en) 2023-12-21
CA3200665A1 (en) 2022-05-12
KR20230104233A (ko) 2023-07-07
WO2022098979A1 (en) 2022-05-12
EP4240755A1 (en) 2023-09-13

Similar Documents

Publication Publication Date Title
KR102775647B1 (ko) 종양을 치료하는 방법
WO2019016772A2 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER
JP2021519771A (ja) 腫瘍を処置する方法
WO2019178217A1 (en) Methods and compositions for treating, diagnosing, and prognosing cancer
JP7418322B2 (ja) Ｄｌｂｃｌ患者サブグループのオビヌツズマブ治療
JP2024506839A (ja) キナーゼ阻害剤を用いてがんを処置する方法
JP2023548590A (ja) 小細胞肺がんの分類と治療のための方法およびシステム
US20240150848A1 (en) Methods and systems for diagnosis, classification, and treatment of small cell lung cancer and other high-grade neuroendocrine carcinomas
JP7777533B2 (ja) Ｎｒｇ１融合体を有するがんの治療のためのポジオチニブの使用
JP2024519782A (ja) がん治療のためのｃｄ２７４変異
JP2024512395A (ja) がんの治療のための方法
WO2024003241A1 (en) Treatment for immuno-oncology resistant subjects with an anti pd-l1 antibody an antisense targeted to stat3 and an inhibitor of ctla-4
JP2023513006A (ja) Ｎｒｇ１融合体を有するがんの治療のためのｅｇｆｒ／ｈｅｒ２チロシンキナーゼインヒビターおよび／またはｈｅｒ２／ｈｅｒ３抗体の使用
US20250049848A1 (en) Methods and compositions for altering a tumor microbiome
JP2024505056A (ja) ポジオチニブを用いてがんを処置する方法
WO2025248505A1 (en) Methods for treating endometrial and ovarian hyperproliferative disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241101

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241101

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260316